210 related articles for article (PubMed ID: 36826832)
1. Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.
Jin M; Jang A; Kim CA; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Eur Thyroid J; 2023 Apr; 12(2):. PubMed ID: 36826832
[TBL] [Abstract][Full Text] [Related]
2. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
[No Abstract] [Full Text] [Related]
3. Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study.
Song E; Kim M; Park S; Park MJ; Kim JA; Roh E; Yu JH; Kim NH; Seo JA; Kim SG; Kim NH; Choi KM; Baik SH; Yoo HJ
Front Endocrinol (Lausanne); 2021; 12():761782. PubMed ID: 34690936
[TBL] [Abstract][Full Text] [Related]
4. Long-term thionamide antithyroid treatment of Graves' disease.
Azizi F; Abdi H; Amouzegar A; Habibi Moeini AS
Best Pract Res Clin Endocrinol Metab; 2023 Mar; 37(2):101631. PubMed ID: 35440398
[TBL] [Abstract][Full Text] [Related]
5. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience.
Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B
Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149
[TBL] [Abstract][Full Text] [Related]
6. [Long-term follow up after antithyroid drug treatment in Graves' disease].
Wille T; Müller B; Noth D; Bürgi U; Diem P
Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
[TBL] [Abstract][Full Text] [Related]
7. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
[TBL] [Abstract][Full Text] [Related]
8. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
Glinoer D; de Nayer P; Bex M;
Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
[TBL] [Abstract][Full Text] [Related]
9. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
[TBL] [Abstract][Full Text] [Related]
10. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A
Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205
[TBL] [Abstract][Full Text] [Related]
12. Preoperative change of thyroid stimulating hormone receptor antibody level: possible marker for predicting recurrent hyperthyroidism in patients with Graves' disease after subtotal thyroidectomy.
Sugino K; Mimura T; Ozaki O; Iwasaki H; Wada N; Matsumoto A; Ito K
World J Surg; 1996 Sep; 20(7):801-6; discussion 806-7. PubMed ID: 8678954
[TBL] [Abstract][Full Text] [Related]
13. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
[TBL] [Abstract][Full Text] [Related]
14. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
15. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
[TBL] [Abstract][Full Text] [Related]
16. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience.
Azizi F
Thyroid; 2020 Oct; 30(10):1451-1457. PubMed ID: 32253999
[No Abstract] [Full Text] [Related]
18. Prediction for recurrence following antithyroid drug therapy for Graves' hyperthyroidism.
Weng H; Tian WB; Xiao ZD; Xu L
Arch Endocrinol Metab; 2023 May; 67(4):e000609. PubMed ID: 37252698
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Lu JY; Chen KH; Shih SR; Wen FY; Wu WC; Chen TC; Hu FC
Endocr Pract; 2023 Feb; 29(2):89-96. PubMed ID: 36396015
[TBL] [Abstract][Full Text] [Related]
20. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]